ReviewJournal of psychopharmacology (Oxford, England)2022
Psychedelics and health behaviour change.
Review in Journal of psychopharmacology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 83 citations in OpenAlex.
- Psychedelic Art and Implications for Mental Health: Randomized Pilot Study.JMIR formative research · 2024Trial
- Well-being as a primary endpoint in clinical trials: a call for consensus.Npj mental health research · 2026Review
- Exploring self-reported health behavior change following naturalistic psychedelic use.Journal of health psychology · 2026Article
- The combination of exercise and psychedelics for the treatment of major depressive disorder.Discover mental health · 2026Article
- Practitioner perspectives on extended difficulties and optimal support strategies following psychedelic experiences: a qualitative analysis.Harm reduction journal · 2025Article
- Exploring practitioners' perceptions of health behavior changes associated with psychedelic experiences.Scientific reports · 2025Article
- The Relationship Between Psychedelic Use and Positive Adult Development in Emerging Adulthood: An Integrative Review.Brain and behavior · 2025Review
- Health-related behavioral changes following the use of psychedelics in naturalistic settings.Preventive medicine reports · 2025Article
- Lysergic Acid Diethylamide (LSD) and the Heart: Exploring the Potential Impacts of LSD on Cardiovascular Function.Cureus · 2025Review
- Population-based estimates of different dosage types of psychedelic use across socio-demographic groups in Germany.Scientific reports · 2025Article
- Can the gut-brain axis provide insight into psilocybin's therapeutic value in reducing stress?Neurobiology of stress · 2025Review
- Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use.PNAS nexus · 2025Article
- Associations between psychedelic-related and meditation-related variables: A longitudinal study.Journal of psychiatric research · 2025Article
- Race/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder.PloS one · 2025Article
- What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial.Therapeutic advances in psychopharmacology · 2025Article
- Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models.Frontiers in systems neuroscience · 2025Review
- An Occupational Perspective on Psychedelic Therapy: A Scoping Review.Canadian journal of occupational therapy. Revue canadienne d'ergotherapie · 2024Article
- From chaos to kaleidoscope: Exploring factors in psychedelic self-treatment for mental health conditions.Journal of psychopharmacology (Oxford, England) · 2024Article
- Psychedelics and sexual functioning: a mixed-methods study.Scientific reports · 2024Article
- Race and ethnicity moderate the associations between lifetime psilocybin use and past year hypertension.Frontiers in psychiatry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Healthful behaviours such as maintaining a balanced diet, being physically active and refraining from smoking have major impacts on the risk of developing cancer, diabetes, cardiovascular diseases and other serious conditions. The burden of the so-called 'lifestyle diseases'-in personal suffering, premature mortality and public health costs-is considerable. Consequently, interventions designed to promote healthy behaviours are increasingly being studied, e.g., using psychobiological models of behavioural regulation and change. In this article, we explore the notion that psychedelic substances such as psilocybin could be used to assist in promoting positive lifestyle change conducive to good overall health. Psilocybin has a low toxicity, is non-addictive and has been shown to predict favourable changes in patients with depression, anxiety and other conditions marked by rigid behavioural patterns, including substance (mis)use. While it is still early days for modern psychedelic science, research is advancing fast and results are promising. Here we describe psychedelics' proposed mechanisms of action and research findings pertinent to health behaviour change science, hoping to generate discussion and new research hypotheses linking the two areas. Therapeutic models including psychedelic experiences and common behaviour change methods (e.g., Cognitive Behaviour Therapy, Motivational Interviewing) are already being tested for addiction and eating disorders. We believe this research may soon be extended to help promote improved diet, exercise, nature exposure and also mindfulness or stress reduction practices, all of which can contribute to physical and psychological health and well-being.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.